- Name: Linfang Li
- Title: Associate Chief Technician
- Email: lilf@sysucc.org.cn
- Phone:
Profile
Permanent staff, Biochemical Laboratory, Department of Clinical Laboratory, Sun Yat-sen University Cancer Center. Responsible for report review of routine biochemical tests. The research focuses on screening novel biomarkers and prognostic evaluation for digestive tract tumors, aiming to identify highly reliable indicators, improve the diagnostic efficiency of tumor laboratory testing and enhance the clinical practicality of laboratory assays.
Interests
Focus on Novel Biomarkers and Prognostic Evaluation of Digestive Tract Tumors
Education
Bachelor of Medical Laboratory Science, Guangdong Medical University , Dongguan, China
Master of Immunology, Sun Yat-sen University, Guangzhou, China
Publications
1. Li, L., Gu, W., Wu, X., Ao, Y., Song, Y., Li, X., & Zeng, Q. (2021). Superiority of fecal carcinoembryonic antigen as diagnosis marker for adenomatous polyposis coli and asymptomatic colorectal cancer. Therapeutic advances in gastroenterology, 14, 17562848211062792.
2. Li L, Xing S, Wu M, et al. (2021) Fecal CEA Has an Advantage in the Diagnosis of Colorectal Cancer at Early Stage. Cancer Control. 2021;28:10732748211048292.
3. Guo S, Li L, Xu B, et al. A Simple and Novel Fecal Biomarker for Colorectal Cancer: Ratio of Fusobacterium Nucleatum to Probiotics Populations, Based on Their Antagonistic Effect. Clin Chem. 2018;64(9):1327-1337.
4. Guo S, Chen F, Li L, et al. Intracellular Fusobacterium nucleatum infection increases METTL3-mediated m6A methylation to promote the metastasis of esophageal squamous cell carcinoma. J Adv Res. 2024;61:165-178.
5. Zeng, Q., Zhou, Z., Zhang, J., Cai, R., Yang, H., Chen, P., & Li, L. (2025). A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers. BMC Cancer. 2025;25(1):112. Published 2025 Jan 21.
6. Wu, M., Zou, F., He, S., Pi, Y., Song, Y., Chen, S., & Li, L. (2025). Serum Osteopontin Enhances Hepatocellular Carcinoma Diagnosis and Predicts Anti-PD-L1 Immunotherapy Benefit. J Hepatocell Carcinoma. 2025;12:729-745. Published 2025 Apr 13.